Đang chuẩn bị liên kết để tải về tài liệu:
báo cáo khoa học: "Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment | Lorizio et al. Genome Medicine 2011 3 64 http genomemedicine.eom content 3 10 64 Genome Medicine RESEARCH Open Access Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment Wendy Lorizio1 2 3 Hope Rugo3 4 Mary S Beattie1 3 5 6 Simone Tchu7 Teri Melese3 8 Michelle Melisko3 4 Alan HB Wu9 H Jeffrey Lawrence10 Michele Nikoloff10 and Elad Ziv1 3 5 6 Abstract Background Pharmacogenetic testing holds major promise in allowing physicians to tailor therapy to patients based on genotype. However there is little data on the impact of pharmacogenetic test results on patient and clinician choice of therapy. CYP2D6 testing among tamoxifen users offers a potential test case of the use of pharmacogenetic testing in the clinic. We evaluated the effect of CYP2D6 testing in clinical practice to determine whether genotype results affected choice of hormone therapy in a prospective cohort study. Methods Women planning to take or currently taking tamoxifen were considered eligible. Participants were enrolled in an informational session that reviewed the results of studies of CYP2D6 genotype on breast cancer recurrence. CYP2D6 genotyping was offered to participants using the AmpliChip CYP450 Test. Women were classified as either poor intermediate extensive or ultra-rapid metabolizers. Results were provided to clinicians without specific treatment recommendations. Follow-up was performed with a structured phone interview 3 to 6 months after testing to evaluate changes in medication. Results A total of 245 women were tested and 235 completed the follow-up survey. Six of 13 46 women classified as poor metabolizers reported changing treatment compared with 11 of 218 5 classified as intermediate extensive or ultra-rapid metabolizers P 0.001 . There was no difference in treatment choices between women classified as intermediate and extensive metabolizers. In multi-variate models that adjusted for age race ethnicity educational status method of referral .